Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Genzyme's Gaucher Drug Shows Positive Results In Follow Up Data Of Phase 2 Trial

Genzyme Corp., a unit of Sanofi-Aventis (SNY: Quote,SNYNF.PK), Wednesday said that a four-year follow-up data from a phase 2 trial for its investigational oral drug 'eliglustat tartrate' for Gaucher disease, showed further improvements across all endpoints.

Sustained or further improvements were observed across all endpoints, including markers of bone disease, at the four-year timepoint, Genzyme said in a statement.

Gaucher disease (pronounced Go-shay) is an inherited genetic disorder, in which patients lack the normal form of glucocerebrosidase, or GCD enzyme that breaks down specific fat molecules. The lack of this enzyme results in the accumulation of fat in liver, spleen and bone marrow. The disease affects about 1 in 100,000 persons in the general population.

Genzyme previously reported that the 52-week phase 2 trial of eliglustat tartrate had met its primary composite endpoint. Patients have continued to receive eliglustat tartrate in the extension portion of the study for over four years. The data from patients on eliglustat tartrate after four years indicate continued or stabilized improvements across all endpoints.

The composite endpoint is clinically meaningful response in at least two of three endpoints i.e. improvements in spleen size, hemoglobin and platelet levels in individual patients.

Register
To receive FREE breaking news email alerts for Sanofi and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Ireland's economy grew for the second consecutive quarter in the three months to June, latest figures from the Central Statistics Office showed Thursday. Gross domestic product grew a seasonally adjusted 1.5 percent sequentially following 2.8 percent expansion in the first quarter, revised from 2.7... A historic referendum that decides the future of Scotland has begun. The Scots are voting Thursday on whether Scotland should become an independent country or stay in the United Kingdom. Voting opened at 7am local time in more than 2,600 polling stations, where voters are given the "Yes" and "No" options to the referendum question: "Should Scotland be an independent country?." More than four milli The European Central Bank announced Thursday the results of its first targeted longer term refinancing operation, or TLTRO, which is aimed to boost liquidity at Eurozone banks to help revive lending to small businesses and households. The central bank announced that 255 bidders were allotted EUR 82.60...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.